Japan­ese bil­lion­aire Hi­roshi Mik­i­tani bankrolls As­pyr­i­an with a $150M mega-round, back­ing a glob­al roll­out plan for PhI­II can­cer ther­a­py

Among the world’s bil­lion­aires, Hi­roshi Mik­i­tani is one of the most promi­nent en­thu­si­asts. Start­ing with 6 staffers and a small sum of cash, he turned Rakuten in­to an on­line pow­er­house in Japan that is ranked among the world’s top e-tail­ers. An icon­o­clast in an econ­o­my dom­i­nat­ed by tra­di­tion­al­ists, he’s man­dat­ed that every­one in his com­pa­ny learn and speak Eng­lish as their first lan­guage. His re­cent ven­tures in­clude a part­ner­ship with Wal­mart for an on­line su­per­mar­ket in Japan. 

And he’s worth an es­ti­mat­ed $7 bil­lion.

Now, Mik­i­tani is putting in the li­on’s share of a $150 mil­lion mega-round in­to a small, pre­vi­ous­ly low-pro­file San Diego biotech he di­rects as chair­man of the board, adding to the eq­ui­ty he had al­ready bought up. And he’s putting some of that trade­mark gung-ho en­thu­si­asm be­hind a new ven­ture that is jump­ing from a small, sin­gle-arm Phase I/II tri­al in ad­vanced, treat­ment-re­sis­tant cas­es straight in­to a Phase III pro­gram.

A chunk of that new mon­ey is be­ing re­served for build­ing the foun­da­tion of their com­mer­cial pro­gram for ASP-1929, ahead of any mid-stage demon­stra­tion of proof-of-con­cept suc­cess. And Rakuten As­pyr­i­an is go­ing all out to build a ful­ly in­te­grat­ed out­fit, with plans to de­vel­op a pipeline of ther­a­peu­tic pro­grams that it plans to mar­ket on its own, with of­fices in the US, Japan and Eu­rope.

Miguel Gar­cia-Guz­man

CEO Miguel Gar­cia-Guz­man tells me that the mid-stage por­tion of ef­fi­ca­cy and safe­ty da­ta from their 42-pa­tient study of their pho­toim­munother­a­py is weeks away from a pub­lic un­veil­ing. But it’s all for­ward mo­tion now that the com­pa­ny has raised a to­tal of $238 mil­lion.

“We have enough con­fi­dence to move in­to a Phase III straight on,” says Gar­cia-Guz­man, point­ing to their lead ef­fort on an EGFR-tar­get­ing ther­a­py for head and neck squa­mous cell car­ci­no­mas. New mid-stage stud­ies are al­so be­ing set up for oth­er can­cers with an EGFR tar­get, which is quite com­mon.

Why the ear­ly con­fi­dence?

The Japan­ese bil­lion­aire is back­ing a new tech­nol­o­gy that was de­vel­oped at the Na­tion­al Can­cer In­sti­tute in the lab of Hisa­ta­ka Kobayashi, an imag­ing ex­pert who made a some­what serendip­i­tous dis­cov­ery that con­ju­gat­ing an an­ti­body with a dye called IRDye700DX (IR700), in­fus­ing it in­to pa­tients and then hit­ting it with a near in­frared light would cre­mate can­cer cells with­out off-tar­get tox­i­c­i­ty. Kobayashi out-li­censed it to As­pyr­i­an Ther­a­peu­tics, which now goes by the name of Rakuten As­pyr­i­an.

Mik­i­tani be­came fa­mil­iar with the work at the NCI as he was hunt­ing down a bet­ter ther­a­py for his fa­ther, who was dy­ing of pan­cre­at­ic can­cer. And while it was too late to save his fa­ther, he seized on it as the next big thing in can­cer, back­ing As­pyr­i­an from the be­gin­ning.

There’s been a lot more work on the tech­nol­o­gy since those ear­ly days at the NCI, says the CEO. The com­pa­ny has been work­ing on laser tech and dif­fer­ent fiberop­tics “to il­lu­mi­nate large in­ter­nal tu­mors, which can be eas­i­ly im­plant­ed in the tu­mor.” Once the fiberop­tics are in­side the tu­mor, you “switch on the light for 5 min­utes (a day af­ter the in­fu­sion), and treat­ment is com­plete.”

If the an­ti­body con­ju­gate is bound to can­cer cells, says Gar­cia-Guz­man, cell mem­brane in­tegri­ty is de­stroyed and necro­sis is trig­gered.

“This is not a phar­ma­co­log­i­cal ef­fect,” he adds, “it’s more bio­phys­i­cal, this al­lows a very tar­get­ed ap­proach.”

Mik­i­tani is the on­ly named in­vestor in this round, but the CEO tells me that he’s the lead play­er, with a ma­jor­i­ty in­ter­est in the com­pa­ny. Oth­er pri­vate in­vestors have stepped in, but Gar­cia-Guz­man says the biotech has steered clear of the VC set, de­ter­mined to con­trol their own fu­ture and main­tain their in­de­pen­dence.

With Mik­i­tani’s sup­port, the com­pa­ny has swelled from a start­up crew of 10 a cou­ple of years ago to 85 now. By the end of this year, you can ex­pect 100 to 110 on the pay­roll. And they plan to keep on grow­ing ag­gres­sive­ly, look­ing to build out all the func­tions of a biotech up­start with glob­al as­pi­ra­tions.

That’s a tall or­der. But Mik­i­tani seems to spe­cial­ize in tall or­ders. And the staff at As­pyr­i­an is all in.


Im­age: Hi­roshi Mik­i­tani at a con­fer­ence in 2018. AP IM­AGES

Biotech and Big Phar­ma: A blue­print for a suc­cess­ful part­ner­ship

Strategic partnerships have long been an important contributor to how drugs are discovered and developed. For decades, big pharma companies have been forming alliances with biotech innovators to increase R&D productivity, expand geographical reach and better manage late-stage commercialization costs.

Noël Brown, Managing Director and Head of Biotechnology Investment Banking, and Greg Wiederrecht, Ph.D., Managing Director in the Global Healthcare Investment Banking Group at RBC Capital Markets, are no strangers to the importance of these tie-ups. Noël has over 20 years of investment banking experience in the industry. Before moving to the banking world in 2015, Greg was the Vice President and Head of External Scientific Affairs (ESA) at Merck, where he was responsible for the scientific assessment of strategic partnership opportunities worldwide.

Credit: Shutterstock

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

Fenlai Tan still gets chills thinking about the darkest day of his life.

Three out of eight lung cancer patients who received a tyrosine kinase inhibitor developed by his company, Betta Pharma, died in the span of a month. Tan, the chief medical officer, was summoned to Peking Union Medical College Hospital, where the head of the clinical trial department told him that the trial investigators would be conducting an autopsy to see if the patients had died of the disease — they were all very sick by the time they enrolled — or of interstitial lung disease, a deadly side effect tied to the TKI class that’s been reported in Japan.

No­var­tis' sec­ond at­tempt to repli­cate a stun­ning can­cer re­sult falls flat

Novartis’ hopes of turning one of the most surprising trial data points of the last decade into a lung cancer drug has taken another setback.

The Swiss pharma announced Monday that its IL-1 inhibitor canakinumab did not significantly extend the lives or slow the disease progression of patients with previously untreated locally advanced or metastatic non-small cell lung cancer when compared to standard of-care alone.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

Peter Nell, Mammoth Biosciences CBO

UP­DAT­ED: Jen­nifer Doud­na spin­out inks a Mam­moth CRISPR deal with Ver­tex worth near­ly $700M

When a company gets its start in gene editing pioneer Jennifer Doudna’s lab, it’s bound to make headlines. But three years in, the fanfare still hasn’t died down for Mammoth Biosciences. Now, the Brisbane, CA-based company is cheering on its first major R&D pact.

Mammoth unveiled a nearly $700 million deal with Vertex on Tuesday morning, good for the development of in vivo gene therapies for two mystery diseases. The stars of the show are Mammoth’s ultra-small CRISPR systems, including two Cas enzymes licensed from Doudna’s lab over the past couple years, Cas14 and Casɸ.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

James Peyer, Cambrian CEO

Brent Saun­ders joins $100M Se­ries C for a com­pa­ny out to be the Bridge­Bio of ag­ing

About a year ago, James Peyer, a CEO and co-founder of the little known longevity biotech Cambrian Biopharma, was trying to find some R&D talent last year when he met with more than a bit of experience in that department: David Nicholson, the former R&D chief of the erstwhile pharma giant Allergan.

It turned out Nicholson already had an interest in Peyer’s field. In their Allergan days, he and COO Brent Saunders held weekly meetups where they tried to figure out how to take the company’s dominance in aesthetics — which, until recently, was often what people meant by anti-aging science — and expertise with more traditional drug development, and use it to make drugs that extend people’s lifespan.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

An­gion's or­gan dam­age drug strikes out again, this time in high-risk kid­ney trans­plant pa­tients

After flopping a test in Covid-19 earlier this year, Angion’s lead organ damage drug has now hit the skids again in kidney transplant patients.

Angion and partner Vifor Pharma’s ANG-3777 failed to beat out placebo in terms of improving eGFR, a measure of kidney function, in patients who had received a deceased donor kidney transplant and were at high risk of developing what is known as delayed graft function, according to Phase III results released Tuesday.

(Photo courtesy Pfizer)

FDA's vac­cine ad­comm votes al­most unan­i­mous­ly in fa­vor of Pfiz­er's Covid-19 vac­cine for younger chil­dren

The FDA’s Vaccines and Related Biological Products Advisory Committee on Tuesday voted 17-0, with one panelist abstaining, that the benefits of the Pfizer-BioNTech Covid-19 vaccine outweigh the risks for children between the ages of five and 12.

The vote will likely trigger a process that could allow the shots to begin rolling out as early as next week.

The vaccine, which is one-third of the adult Pfizer dose, proved to be about 90% effective in a placebo-controlled trial in which about 1,500 kids in this age range received the vaccine, and only about 12% of those receiving the vaccine had any adverse event. All serious adverse events in the trial were unrelated to the vaccine.

Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)

Mod­er­na chips in fur­ther on African vac­cine sup­ply — but ad­vo­cates are call­ing for even more

In a sign of its growing commitment to the continent, Moderna will supply up to 110 million doses of its Covid-19 vaccine to the African Union, the company announced Tuesday. And CEO Stéphane Bancel said it’s just the first step.

“We believe our vaccine can play an important role in addressing the needs of low-income countries given its combination of high Phase 3 efficacy against COVID-19, strong durability in the real-world evidence, and superior storage and handling conditions. We recognize that access to COVID-19 vaccines continues to be a challenge in many parts of the world and we remain committed to helping to protect as many people as possible around the globe,” Bancel said in a statement.

An image of Alzheimer's brain tissue. The red show gingipains, a protein from P. gingivalis, intermixing with neurons (yellow) and glial cells (green)

An Alzheimer's dark­horse fails its first big tri­al, but of­fers hope for a long-over­looked hy­poth­e­sis

Three years ago, Cortexyme emerged out of obscurity with some big-name backers and an unorthodox approach to treating Alzheimer’s.

They moved their drug into a pivotal study the next year, offering one of the first major tests for a hypothesis that has fluttered on the outskirts of Alzheimer’s research for decades: that, in many cases, the disease is driven by infectious agents — the havoc they wreak in the brain and the inflammation the body uses to try to fend them off. And that quashing the infection could slow patients’ cognitive decline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.